Ozempic Cost in Pennsylvania (2026): Prices, Insurance, and Savings Options

What Ozempic Costs at Pennsylvania Pharmacies in 2026

The manufacturer list price set by Novo Nordisk for Ozempic is $998 per month across all pen strengths, and Pennsylvania retail pharmacies reflect this figure for uninsured or cash-pay patients. This price applies whether a patient fills at a chain like CVS, Rite Aid, or Walgreens, or at an independent pharmacy in Philadelphia, Pittsburgh, or anywhere else in the commonwealth. Prices do not vary by dose pen (0.25 mg, 0.5 mg, 1 mg, or 2 mg) because each carton contains a 4-week supply [1].

Pennsylvania has no state-level drug price cap or discount mandate that would reduce this retail figure. The out-of-pocket number a patient actually pays depends entirely on insurance coverage, manufacturer coupons, or alternative formulations like compounded semaglutide.

For context, that $998 monthly figure aligns with the national average. A 2023 analysis published in Annals of Internal Medicine found that GLP-1 receptor agonist list prices in the United States exceed those in other high-income countries by 3- to 8-fold [2]. The same study estimated that a cost-effective price for semaglutide would fall between $100 and $500 per year based on quality-adjusted life-year thresholds. That gap between list price and value-based price is the reason savings strategies matter so much for Pennsylvania residents filling this prescription.

Pennsylvania Insurance Coverage for Ozempic

Most major commercial health insurers operating in Pennsylvania cover Ozempic for its FDA-approved indication of type 2 diabetes, though nearly all require prior authorization. Plans from Highmark Blue Cross Blue Shield, UPMC Health Plan, Aetna, Cigna, and Independence Blue Cross typically include Ozempic on their formularies at a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) level. Copays for commercially insured patients generally range from $25 to $150 per month depending on the plan's tier structure and deductible status.

Prior authorization criteria usually require documentation that the patient has a confirmed HbA1c of 7% or higher, has tried or is intolerant to metformin, and is using Ozempic specifically for glycemic control [1]. Coverage for off-label weight loss use (in patients without type 2 diabetes) is far less common on commercial plans, though a growing number of Pennsylvania employers are adding anti-obesity medication benefits.

Dr. Caroline Apovian, a past president of The Obesity Society, has stated: "The biggest barrier to GLP-1 receptor agonist access in the United States is not clinical evidence. It is payer restrictions that treat obesity as a lifestyle choice rather than a chronic disease" [3].

Patients who are denied coverage should request a peer-to-peer review. Pennsylvania insurance regulations require insurers to provide a written denial explanation and an appeals pathway. The SUSTAIN clinical trial program, which demonstrated HbA1c reductions of 1.2% to 1.8% with semaglutide across multiple studies, provides strong clinical justification for appeal letters [4].

Does Pennsylvania Medicaid Cover Ozempic?

Pennsylvania Medicaid, administered through the Department of Human Services and managed care organizations (MCOs) such as UPMC for You, AmeriHealth Caritas, and Highmark Wholecare, covers Ozempic with prior authorization for type 2 diabetes. The prior authorization process requires prescribers to confirm a diabetes diagnosis (ICD-10 E11.x), document inadequate glycemic control on first-line therapy, and specify the target dose.

Coverage is limited to the FDA-approved diabetes indication. Pennsylvania Medicaid does not currently cover Ozempic (or Wegovy) for weight management alone, consistent with most state Medicaid programs nationwide. A 2024 KFF analysis found that only 16 states had any form of Medicaid coverage for anti-obesity medications [5].

Medicaid patients in PA face no copay or a nominal copay (typically $1 to $3) once the prior authorization is approved. Processing times for PA through MCOs average 3 to 7 business days, though urgent or expedited requests can be completed in 24 to 72 hours.

For Medicaid enrollees who do not have type 2 diabetes but do have obesity, the current option is to discuss compounded semaglutide (paid out of pocket) or to ask about clinical trial enrollment at Pennsylvania academic medical centers including Penn Medicine and UPMC.

Compounded Semaglutide in Pennsylvania: Legality, Pricing, and Risks

Compounded semaglutide is available in Pennsylvania through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines from the FDA's section 503A of the Federal Food, Drug, and Cosmetic Act. A valid prescription from a licensed prescriber is required [6].

The average price for compounded semaglutide from a Pennsylvania-licensed 503A pharmacy is approximately $199 per month, roughly 80% less than brand-name Ozempic. Compounded formulations are typically supplied as multi-dose vials for subcutaneous injection, with the patient drawing individual doses using insulin syringes.

There are real differences between brand Ozempic and compounded semaglutide that patients should understand. Brand Ozempic uses a pre-filled, dose-dialed pen injector manufactured under FDA-approved cGMP conditions with batch-level quality testing. Compounded preparations are mixed per-patient or in small batches and are not FDA-approved, though they are FDA-regulated. The FDA has repeatedly warned about safety concerns with some compounded semaglutide products, including reports of incorrect concentrations, sterility failures, and salt-form substitutions (semaglutide sodium vs. semaglutide base) [7].

Pennsylvania patients considering compounded semaglutide should verify three things: (1) the pharmacy holds a current Pennsylvania Board of Pharmacy compounding license, (2) the pharmacy uses semaglutide base (not sodium salt) in concentrations that match the prescribed dose, and (3) the pharmacy can provide a certificate of analysis from a third-party testing lab for each batch. Patients should also confirm their prescriber will monitor them with the same lab schedule (HbA1c every 3 months, renal function annually) used for brand Ozempic.

The legal status of compounded semaglutide nationally remains in flux. The FDA removed semaglutide from its drug shortage list in February 2024, which under normal circumstances would have triggered a wind-down period for compounding. Litigation and congressional interest have extended availability, but Pennsylvania patients should be aware that regulatory changes could affect access.

The Novo Nordisk Savings Card and Other Discount Programs

The Novo Nordisk Ozempic Savings Card is the single most effective discount tool for commercially insured Pennsylvania residents. Eligible patients pay as little as $25 for a 1-month, 2-month, or 3-month prescription supply, with Novo Nordisk covering up to $150 per fill for 24 months [1]. Eligibility requirements include: commercial or private insurance that covers Ozempic, a valid prescription, and age 18 or older. The card does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA).

Beyond the manufacturer card, Pennsylvania patients have several other cost-reduction pathways:

GoodRx and RxSaver coupons. These aggregator platforms negotiate cash-pay discounts with pharmacy benefit managers. Typical GoodRx prices for Ozempic in Pennsylvania range from $850 to $935 per month, a modest but real reduction from the $998 list price.

Patient assistance programs. Novo Nordisk's Patient Assistance Program (PAP) provides free Ozempic to uninsured patients who meet income thresholds (generally at or below 400% of the federal poverty level). Pennsylvania residents can apply through NovoCare at 1-888-809-3942.

340B pharmacies. Patients who receive care at federally qualified health centers (FQHCs) or other 340B-covered entities in Pennsylvania may access Ozempic at significantly reduced prices. Pennsylvania has over 50 FQHCs across the state, concentrated in Philadelphia, Pittsburgh, Allentown, and Erie.

Medicare Part D. Pennsylvania Medicare beneficiaries should note that the Inflation Reduction Act capped insulin copays at $35 per month starting in 2023, and beginning in 2025, Part D out-of-pocket costs are capped at $2,000 annually across all covered drugs. For Medicare patients whose Part D plan covers Ozempic, this cap limits annual exposure regardless of the drug's list price [8].

Telehealth Access to Ozempic in Pennsylvania

Pennsylvania permits telehealth prescribing of Ozempic statewide, with no requirement for an initial in-person visit for established patient-prescriber relationships. Act 167 of 2020 codified telehealth parity in Pennsylvania, requiring commercial insurers to cover telehealth services at the same rate as in-person visits [9].

This means Pennsylvania residents in rural areas (including counties in the northern tier, central PA, and the Poconos where endocrinologist access is limited) can obtain Ozempic prescriptions through video or phone consultations. Several national telehealth platforms, including HealthRX, offer semaglutide prescribing with licensed Pennsylvania providers.

Telehealth prescribers must hold an active Pennsylvania medical license or practice under the Interstate Medical Licensure Compact, which Pennsylvania joined. The prescriber must perform an appropriate clinical evaluation, review labs (HbA1c, metabolic panel), and document medical necessity before prescribing.

One practical note: telehealth visits work well for Ozempic initiation and dose titration, but patients still need periodic in-person lab draws. Most telehealth platforms partner with Quest Diagnostics or Labcorp, both of which have extensive Pennsylvania locations, for blood work.

How Ozempic Doses Affect Cost in Pennsylvania

Ozempic pricing in Pennsylvania is per-pen-carton, not per-milligram. Each carton provides a 4-week supply at the prescribed dose level, and the $998 list price applies uniformly across all dose strengths. This pricing structure means that cost does not change as patients titrate upward through the standard dosing schedule [1]:

Weeks 1 through 4: 0.25 mg once weekly (initiation dose). Weeks 5 through 8: 0.5 mg once weekly (first therapeutic dose). Week 9 onward: 1 mg once weekly if additional glycemic control is needed. Maximum dose: 2 mg once weekly, approved in 2022.

The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide 0.5 mg reduced HbA1c by 1.5% vs. 1.1% for dulaglutide 0.75 mg, and semaglutide 1 mg reduced HbA1c by 1.8% vs. 1.4% for dulaglutide 1.5 mg [4]. These dose-response data support the clinical rationale for titrating to higher doses when glycemic targets are not met, without additional cost impact.

For patients using compounded semaglutide, pricing may vary by dose. Some 503A pharmacies charge a flat monthly fee regardless of concentration, while others price by milligram. Patients should request a dose-based price schedule before committing to a compounding pharmacy.

Comparing Ozempic Costs to Other GLP-1 Options in Pennsylvania

Pennsylvania patients weighing their GLP-1 receptor agonist options should consider relative cost alongside clinical profile. Monthly list prices in 2026 for the major branded GLP-1 RAs are:

Ozempic (semaglutide injection): $998. Wegovy (semaglutide injection, obesity indication): $1,349. Mounjaro (tirzepatide injection): $1,023. Zepbound (tirzepatide injection, obesity indication): $1,059. Trulicity (dulaglutide injection): $970. Rybelsus (oral semaglutide): $935.

Tirzepatide, the dual GIP/GLP-1 receptor agonist in Mounjaro, showed superior HbA1c reduction compared to semaglutide 1 mg in the SURPASS-2 trial (N=1,879). Tirzepatide 15 mg reduced HbA1c by 2.3% vs. 1.86% for semaglutide 1 mg at 40 weeks [10]. Whether that incremental efficacy justifies the slightly higher list price depends on the patient's glycemic gap and insurance formulary positioning.

For Pennsylvania patients whose primary goal is weight loss rather than glycemic control, the relevant comparison is Wegovy vs. Zepbound. Wegovy (semaglutide 2.4 mg) produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) [11]. Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [12]. Both require separate insurance authorization from their diabetes-indication counterparts.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit (including semaglutide) as preferred second-line agents after metformin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease [13].

What Pennsylvania Patients Should Know Before Starting Ozempic

Before filling a first Ozempic prescription in Pennsylvania, patients should complete four steps. First, confirm insurance coverage and tier placement by calling the number on the back of the insurance card and requesting a formulary check for semaglutide (Ozempic). Second, ask the prescriber to submit prior authorization proactively rather than waiting for a pharmacy rejection. Third, enroll in the Novo Nordisk savings card program at NovoCare.com if commercially insured. Fourth, locate a preferred pharmacy. Some Pennsylvania insurers mandate specialty pharmacy dispensing for Ozempic, which may mean mail-order delivery rather than local pickup.

Patients should also prepare for the most common side effects. Pooled SUSTAIN trial data show nausea in 15% to 20% of patients during dose titration, typically resolving within 4 to 8 weeks [1]. Eating smaller meals, avoiding high-fat foods, and staying hydrated reduce nausea risk during the titration phase.

The prescribing information carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies with semaglutide. Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1]. Pennsylvania prescribers should screen for these conditions before initiating therapy, and patients should report any neck mass, dysphagia, or persistent hoarseness promptly.

Baseline labs before starting Ozempic should include HbA1c, fasting glucose, comprehensive metabolic panel (to assess renal and hepatic function), lipid panel, and thyroid function tests. Follow-up HbA1c testing at 3-month intervals guides dose titration decisions [13].